Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fourth Time’s The Charm? Teva Cites Colloids in Latest Attempt to Convince FDA to Require Clinical Trials for Generic Copaxone

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has rejected three previous citizen petitions from Teva seeking to impose barriers on future generic filers for the MS drug.


Related Content

After CEO’s Abrupt Resignation, Teva Management Emphasizes Stability
Generic Copaxone Looms; Teva Fights And Prepares For Next Chapter
Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent
A More Disciplined Teva Gets Lukewarm Reception From Street
Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan
The Lovenox Benchmark: Copaxone "Far More Complex," Teva Argues In Anti-Generic Petition


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts